Skip to main content

Research Repository

Advanced Search

The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial.

Hollingworth, Milo; Woodhouse, Lisa J; Law, Zhe K; Ali, Azlinawati; Krishnan, Kailash; Dineen, Robert A; Christensen, Hanne; England, Timothy J.; Roffe, Christine; Werring, David; Peters, Nils; Ciccone, Alfonso; Robinson, Thompson; Członkowska, Anna; Bereczki, Dániel; Egea-Guerrero, Juan José; Ozturk, Serefnur; Bath, Philip M.; Sprigg, Nikola; England, Timothy J; Bath, Philip M

Authors

Milo Hollingworth

Lisa J Woodhouse

Zhe K Law

Azlinawati Ali

Kailash Krishnan

Robert A Dineen

Hanne Christensen

Timothy J. England

David Werring

Nils Peters

Alfonso Ciccone

Thompson Robinson

Anna Członkowska

Dániel Bereczki

Juan José Egea-Guerrero

Serefnur Ozturk

Philip M. Bath

Nikola Sprigg

Timothy J England

Philip M Bath



Abstract

An important proportion of patients with spontaneous intracerebral hemorrhage (ICH) undergo neurosurgical intervention to reduce mass effect from large hematomas and control the complications of bleeding, including hematoma expansion and hydrocephalus. The Tranexamic acid (TXA) for hyperacute primary IntraCerebral Hemorrhage (TICH-2) trial demonstrated that tranexamic acid (TXA) reduces the risk of hematoma expansion. We hypothesized that TXA would reduce the frequency of surgery (primary outcome) and improve functional outcome at 90 days in surgically treated patients in the TICH-2 data set. Participants enrolled in TICH-2 were randomized to placebo or TXA. Participants randomized to either TXA or placebo were analyzed for whether they received neurosurgery within 7 days and their characteristics, outcomes, hematoma volumes (HVs) were compared. Characteristics and outcomes of participants who received surgery were also compared with those who did not. Neurosurgery was performed in 5.2% of participants (121/2325), including craniotomy (57%), hematoma drainage (33%), and external ventricular drainage (21%). The number of patients receiving surgery who received TXA vs placebo were similar at 4.9% (57/1153) and 5.5% (64/1163), respectively (odds ratio [OR] 0.893; 95% CI 0.619-1.289; P-value = .545). TXA did not improve outcome compared with placebo in either surgically treated participants (OR 0.79; 95% CI 0.30-2.09; P = .64) or those undergoing hematoma evacuation by drainage or craniotomy (OR 1.19 95% 0.51-2.78; P-value = .69). Postoperative HV was not reduced by TXA (mean difference -8.97 95% CI -23.77, 5.82; P-value = .45). TXA was not associated with less neurosurgical intervention, reduced HV, or improved outcomes after surgery. [Abstract copyright: Copyright © 2024 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the Congress of Neurological Surgeons.]

Citation

Hollingworth, M., Woodhouse, L. J., Law, Z. K., Ali, A., Krishnan, K., Dineen, R. A., …Bath, P. M. (in press). The Effect of Tranexamic Acid on Neurosurgical Intervention in Spontaneous Intracerebral Hematoma: Data From 121 Surgically Treated Participants From the Tranexamic Acid in IntraCerebral Hemorrhage-2 Randomized Controlled Trial. Neurosurgery, 95(3), 605-616. https://doi.org/10.1227/neu.0000000000002961

Journal Article Type Article
Acceptance Date Jan 28, 2024
Online Publication Date May 24, 2024
Deposit Date Jun 10, 2024
Journal Neurosurgery
Print ISSN 0148-396X
Electronic ISSN 1524-4040
Publisher Lippincott, Williams & Wilkins
Peer Reviewed Peer Reviewed
Volume 95
Issue 3
Pages 605-616
DOI https://doi.org/10.1227/neu.0000000000002961
Public URL https://keele-repository.worktribe.com/output/847477